



Bcl-2 Monoclonal Mouse Anti-Bcl-2 Clone BCL2/A4

REF 014-1122

Ready-To-Use ■ 100 Tests / 50 Tests

Concentrate ■ 1mL

INTENDED USE

IVD For in vitro diagnostic use.

Celerus monoclonal mouse anti-Bcl-2, clone BCL2/A4, is intended for laboratory use in identifying the Bcl-2 antigen in normal or neoplastic tissue using light microscopy. It may be used with frozen or with formalin-fixed paraffin-embedded tissue.

Positive results aid in the classification of normal and abnormal cells/tissues and serve as an adjunct to conventional histopathology. The clinical interpretation of any positive staining or its absence should be complemented by morphological and histological studies with proper controls. Evaluations should be made by a qualified individual in conjunction with the patient's clinical history and other diagnostic test results.

Refer to the Wave Instrument Operator's Manual for additional information concerning Materials Required but Not Provided; Storage; Staining Procedure; Troubleshooting; Interpretation of Staining; and General Limitations.

SUMMARY AND EXPLANATION

Bcl-2 is an integral outer mitochondrial membrane protein that blocks the apoptotic death of certain cells such as lymphocytes. Constitutive expression of Bcl-2 may result from translocation of the BCL2 gene to the Ig heavy chain locus, and is thought to be the cause of follicular lymphoma. This antibody may be useful in differentiating follicular lymphomas from reactive lymph node hyperplasias.

PRINCIPLE OF PROCEDURE

Immunohistochemistry is a multi-step process to identify specific cell markers within tissue biopsies or tumor specimens. The sequential steps include antigen retrieval (optional), antibody application, and antibody visualization followed by optional counterstaining. Specimens are then coverslipped and observed under light microscopy by trained personnel. Normally, multiple antibodies are tested to determine lineage and cell cycle markers. The Celerus Wave is an automated instrument that performs immunohistochemistry stains. For further information on the staining procedure, refer to the Celerus Wave Operator's Manual.

MATERIALS AND METHODS

Reagent Provided

Clone
BCL2/A4

Ig Class
IgG₁, kappa

Immunogen

Recombinant Human Bcl-2 Alpha

Ready-To-Use in Primary Antibody Cartridge

Celerus anti-Bcl-2 is provided with ProClin 300 as a preservative, in a Primary Antibody Cartridge (PAC), a self-contained dispenser of reagents. Each PAC contains sufficient reagent to complete 50 or 100 stained slides. PACs must remain upright to avoid spilling. PAC must be primed before first use. See Celerus Wave Operator's Manual for details.

Concentrated Antibody

Liquid

Liquid concentrated antibody is provided containing 15 mM sodium azide as a preservative and 1% bovine serum albumin as a carrier protein.

Lyophilized

Lyophilized antibody is provided containing 15mM sodium azide as a preservative. Reconstitute vial with 1.0 ml distilled water.

Dilution

The suggested dilution is 1:25–1:50. This is a guide only and users should determine their own optimal working dilutions.

SPECIFICITY

Human Bcl-2 oncoprotein.

MATERIALS REQUIRED BUT NOT PROVIDED

- Wave instrument
- Wave slide rack
- Positively-charged microscope slides, appropriately labeled
- Timer
- Celerus Riptide for antigen retrieval (or equivalent)
- Celerus Target Retrieval Solution (or equivalent)
- Slide drying chamber
- Xylene or xylene substitute
- Reagent alcohol or ethyl alcohol
- Distilled or deionized water
- TBS wash buffer, pH 7.6
- Positive and negative tissue controls
- Celerus Negative Control Reagent (or equivalent)
- Mounting Medium
- Cover slips

STORAGE AND HANDLING

Ready-to-Use PAC, Liquid Concentrated and Lyophilized Antibody

Store reagent at 2–8 °C. Do not freeze. The reagent is stable until the expiration date on the container. Do not use reagent after the expiration date, as the activity cannot be ensured.

Reconstituted Antibody

For reconstituted antibody, the reagent is stable for at least two months when stored at 4 °C. For long-term storage it is recommended that aliquots of the antibody be stored at -20 °C. Repeated freezing and thawing of the antibody should be avoided.

There are no signs to indicate instability of this reagent. To ensure a valid staining assay, the use of positive and negative tissue controls is recommended. Contact your Celerus representative if there are stability concerns prior to the expiration date.

PRECAUTIONS

- For professional users.
- Minimize microbial contamination of reagents or an increase in nonspecific staining may occur.
- As with any product derived from biological sources, proper handling procedures should be used.
- A Material Safety Data Sheet is available for professional users on request.
- ProClin 300 is classified per applicable European Community (EC) Directives as: Irritant (Xi). The following are the appropriate Risk (R) and Safety (S) phrases.



R36 Irritating to eyes

R43 May cause sensitization by skin contact

S24 Avoid contact with skin

S26 In case of contact with eyes, rinse immediately with plenty of water and seek medical advice

S35 This material and its container must be disposed of in a safe way

S37/39 Wear suitable gloves and eye/face protection

S46 If swallowed, seek medical advice immediately and show this container or label.

WASTE DISPOSAL

Adhere to all local laws when disposing of the PAC.

PACKAGING DAMAGE

DO NOT USE a PAC if it is leaking, has leaked, has spilled, cannot be primed, or has visually apparent physical damage.

PRODUCT-SPECIFIC LIMITATIONS

Bcl-2 antibody, when used on the Wave instrument, detects antigens that survive routine formalin fixation, tissue processing, and sectioning. Users who deviate from recommended test procedures are responsible for interpretation and validation of patient results.

SPECIMEN COLLECTION AND HANDLING

Formalin-fixed paraffin embedded (FFPE) tissues, frozen tissues, or smears are suitable for use. Wave detection kits have been optimized for tissues fixed with 10% formalin. Ideally, each 4–6µ tissue section should be placed on charged slides on the lower 2/3 of the slide. Very large sections should be placed 1/4 inch below the lower end of the slide label.

Slides should be baked overnight at 37 °C, or at 60 °C for one hour.

Use standard histochemical techniques to deparaffinize processed slides. For uniformity of staining results, it is recommended that target retrieval be performed using the Celerus Riptide and Celerus Target Retrieval Solution (or equivalent) at 112 °C for 5 minutes. Insert slides into the Wave Instrument according to the staining grid provided by the instrument software. Avoid drying of the tissue specimen during this process. After all slides to be stained have been inserted and reagents mounted on the instrument, start the staining run.

When the slides have completed the staining run, remove them from the instrument, coverslip, and view under light microscopy.

RESULTS EXPECTED/ PERFORMANCE CHARACTERISTICS

Normal Tissues

Anti-Bcl-2 stains the cytoplasm and membrane of lymphocytes in the mantle zones and T-cell areas of lymphoid tissue, but only a few cells in germinal centers. Staining has also been observed in some epithelia, including prostate, thyroid, and breast.

Abnormal Tissues

Anti-Bcl-2 stains T-cell lymphomas and follicular lymphomas. Staining has also been observed on some breast carcinomas, carcinoid tumors, Ewing's sarcoma, seminomas, and undifferentiated carcinomas.

REFERENCES

LeBrun DP, Ngan BY, Weiss LM, Huie P, Warnke RA, Cleary ML. The Bcl-2 in Hodgkin's disease arising in the setting of follicular non-Hodgkin's lymphoma. *Blood* 1994; 83:223-230.

Ishida H, Irie K, Itoh T, Furukawa T, Tokunaga O. The prognostic significance of p53 and Bcl-2 expression in lung carcinoma and its correlation with Ki-67 growth fraction. *Cancer* 1997; 80:1034-1045.

Lee H, Koo JY, Jung WH. Correlations of Bcl-2 expression with clinicopathological features in breast cancer. *Yonsei Medical Journal* 1997; 38:206-211.

Matsushima H, Kitamura T, Goto T, Hosaka Y, Homma Y, Kawabe K. Combined analysis with Bcl-2 and p53 immunostaining predicts poorer prognosis in prostatic carcinoma. *J Urol*. 1997;158:2278-2283.

Joensuu H, Pylkkänen L, Toikkanen S. Bcl-2 protein expression and long-term survival in breast cancer. *Am J Pathol*. 1994;145:1191-1198.

Krajewska M, Fenoglio-Preiser C, Krajewski S, Song K, MacDonald JS, Stemmerman G, Reed JC. Immunohistochemical analysis of Bcl-2 family proteins in adenocarcinomas of the stomach. *Am J Pathol*. 1996; 149:1449-1457.



Vector Laboratories, Ltd.
3 Accent Park, Bakewell Road
Orton Southgate, Peterborough
PE2 6XS, England

Celerus Diagnostics
1005 Mark Avenue
Carpinteria, CA 93013 USA

TECHNICAL SUPPORT 888-444-3613
CUSTOMER SERVICE 888-444-8918

www.celerusdiagnostics.com